At Newcells Biotech, we specialise in the large-scale production of retinal organoids for the purpose of in vitro toxicology efficacy studies and disease modelling. Our differentiation protocols generate organoids which are fully stratified with the presence of
Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal organoids from human induced pluripotent stem cells (hiPSCs) from Newcastle University. The acquired technology will add to the growing portfolio of proprietary technologies that Newcells
The retina is the means through which most people primarily perceive the world and for children particularly, visual defects can affect educational, social and emotional development.1 The importance of retinal disease, in
Retinitis pigmentosa (RP) is a group of degenerative disorders of the retina, caused by mutations in one of more than 60 genes, including the genes for making rhodopsin, pre-mRNA processing factors and usherin. The genes
Retinal organoids are becoming a powerful tool in the process of drug discovery, as recently shown by researchers at Newcells Biotech and Newcastle University in a study led by Professor Majlinda Lako
